The H1 2026 update analyses investment in Swiss start-ups during the first six months and provides an insight into the ...
ZuriQ has raised USD 25.5 million in a seed round to scale the trapped-ion quantum processors it is building on a two-dimensional chip architecture. The round was led by Quantonation, and includes ...
The seven-figure pre-seed round drew several VC offices and angel investor: xdeck, HEARTFELT_, OMA Business Angels, superangels, Prequel Ventures and PRXS Technology and Investment, together with ...
NYU Grossman School of Medicine is the first clinical site to participate in the SHIELD study, giving the company the opportunity to evaluate VENUS SHELL™ in a leading radiation oncology center in the ...
Das St.Galler Startup Humboldt AI hat eine KI-basierte Lösung zur Optimierung von Lebensläufen entwickelt. Nach dem Marktstart im Januar 2026 wurde die Plattform bereits von mehreren tausend Personen ...
Das 2024 von Martina Lambaré und Morena Frehner gegründete Zürcher Startup Matcha and Friends vertreibt Matcha sowie passendes Zubehör über den eigenen Onlineshop. Ausserdem ist der Matcha ...
Arcoris bio has signed a distribution agreement to take its biomarker-detection kits into Europe and North America, Hi-D Imaging has secured expanded FDA clearance for its AI-driven heart-valve ...
MoleSense is developing a Wear & Forget platform for continuous hormone monitoring that unifies ultra-low-power on-demand sedentary sweat extraction with aptamer-based multi-hormone nanobiosensing.
FF: The exchange among participants should not be underestimated either. They come from diverse backgrounds and have different ideas. We actively encourage cohesion and trust among them through team ...
DiverSsiTy is the winner of the global AI for Good Innovation Factory contest. UNBOUUND CEO and Founder Julien Wen Hsieh was awarded with a scientific Grand Prize and Urbio was named Heat Network ...
Erneuerbare Energien langfristig und kosteneffizient zu speichern, ist eine der zentralen Herausforderungen auf dem Weg zu ...
The study will be conducted at the Phase I Clinical Trial Centre, under the Department of Clinical Oncology of The Chinese University of Hong Kong. The regulatory approval authorizes Pilatus to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results